Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations

Executive Summary

DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.


Related Content

AASLD Briefs: Hepatitis C
Ambit IPO Ambles Out; Portola And Bluebird Prepare
Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review
Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review
Theravance’s Persistence On Telavancin Rewarded With Positive Cmte. Vote
Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts